TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11773150

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 100 microg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 20 microg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 60 microg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Filgrastim (control group, n = 8)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 20, 60, or 100 microg/kg
Number of subjects: 36
Study: 9436336

Group type: EXPERIMENTAL
Intervention: Senna (0.4 mL daily)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lactulose (15 mL daily)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 91
Study: 7662751

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 72

Group type: COMPARATOR
Intervention: Practice (no feedback)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Noncontingent EMG feedback
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low awareness biofeedback group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High awareness biofeedback group
Number of subjects: 72
Study: 2520620

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily (b.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine four times daily (q.d.s.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 145354

Group type: EXPERIMENTAL
Intervention: Thymoxamine eye-drops (0.2%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ephedrine (5%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ephedrine (5%) together with tropicamide (0.5%)
Number of subjects: 12
Study: 31633185

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 72
Study: 30519766

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27798417

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 3620

Group type: COMPARATOR
Intervention: Other Angiotensin-converting enzyme inhibitors
Number of subjects: 3620
Study: 25581921

Group type: EXPERIMENTAL
Intervention: Web access to PAP usage data
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Web access to PAP usage data with financial incentive
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Functional Outcomes of Sleep Questionnaire
Number of subjects: 138
Study: 23933232

Group type: EXPERIMENTAL
Intervention: Cooling the skin to 20 C
Number of subjects: 12

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch application (all sites)
Number of subjects: 12
Study: 20950961

Group type: EXPERIMENTAL
Intervention: 4D-CT scanning techniques
Number of subjects: 9
Study: 19038356

Group type: EXPERIMENTAL
Intervention: Salbutamol 600 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 120 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16473753

Group type: EXPERIMENTAL
Intervention: Somatic acupuncture
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Somatic acupuncture plus auriculotherapy
Number of subjects: 62
Study: 15663229

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16886330

Group type: EXPERIMENTAL
Intervention: Antiparasitic treatment with metronidazole
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22
Study: 9165632

Group type: EXPERIMENTAL
Intervention: Desipramine and traditional neuroleptics
Number of subjects: 0
Study: 8384097

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3706817

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 7
Study: 31124619

Group type: EXPERIMENTAL
Intervention: Veno-venous extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 0
Study: 29716637

Group type: EXPERIMENTAL
Intervention: Ketamine (subdissociative dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 26877169

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 123
Study: 25037206

Group type: EXPERIMENTAL
Intervention: Naltrexone 50-100 mg/d (flexible dosing)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22700860

Group type: EXPERIMENTAL
Intervention: Prednisone (1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 58
Study: 20020107

Group type: EXPERIMENTAL
Intervention: 0.5 per thousand alcohol administration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17627745

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone treatment (300 mcg/day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 15369884

Group type: EXPERIMENTAL
Intervention: Multi-professional education (MPE)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Uni-professional groups
Number of subjects: 121
Study: 11464446

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 826

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 826
Study: 9755360

Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 7
Study: 7735153

Group type: EXPERIMENTAL
Intervention: Simultaneous contralateral sound stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesions affecting the auditory afferent pathway
Number of subjects: 0
Study: 3293092

Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg IV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 4917915

Group type: EXPERIMENTAL
Intervention: Monovalent inactivated vaccine of the Hong Kong strain of influenza A virus
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Polyvalent vaccine containing only pre‐1968 Asian viruses
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Intranasal spray of the Hong Kong vaccine in addition to injected Asian vaccine
Number of subjects: 1601
Study: 29410606

Group type: EXPERIMENTAL
Intervention: 400 mg lemon verbena extract once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 28145421

Group type: EXPERIMENTAL
Intervention: Higher adherence to the Nordic Nutrition Recommendations (NNR) as measured by the Healthy Food Intake Index (HFII)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Higher adherence to the NNR as measured by HFII
Number of subjects: 137
Study: 26429636

Group type: EXPERIMENTAL
Intervention: Low dose CT screening
Number of subjects: 1329506
Study: 23633626

Group type: EXPERIMENTAL
Intervention: Neural Tissue Management (NTM) - brief education, manual therapy, and nerve gliding exercises for 4 treatments over 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Advice to remain active (Control) - instruction to continue usual activities
Number of subjects: 60
Study: 21245962

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study: 18458144

Group type: EXPERIMENTAL
Intervention: Reproductive risk factors (number of children born)
Number of subjects: 14661

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 14661

Group type: EXPERIMENTAL
Intervention: Non-European ancestry
Number of subjects: 14661

Group type: EXPERIMENTAL
Intervention: Preeclampsia/eclampsia
Number of subjects: 14661

Group type: EXPERIMENTAL
Intervention: Irregular periods
Number of subjects: 14661

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 14661
Study: 17313010

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Quchi (LI 11) and Hegu (LI 4) on the affected side after raising handclasp of Bobath
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raising handclasp of Bobath after electroacupuncture at Quchi (LI 11) and Hegu (LI 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple electroacupuncture or exercise therapy
Number of subjects: 0
Study: 12650654

Group type: EXPERIMENTAL
Intervention: Controlling breathing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Music audiotape
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 11052431

Group type: EXPERIMENTAL
Intervention: 100% oxygen (Oxygen group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50% oxygen (Air group)
Number of subjects: 30
Study: 9471669

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime for 12 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo at bedtime for 12 months
Number of subjects: 50
Study: 7920941

Group type: EXPERIMENTAL
Intervention: NO and Pg E1 combination
Number of subjects: 50

Group type: COMPARATOR
Intervention: NO alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pg E1 alone
Number of subjects: 50
Study: 3883738

Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg orally (single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg orally (long-term treatment, 3 times daily for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard therapy with digitalis and diuretics (Control)
Number of subjects: 10
Study: 29611171

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 30184031

Group type: EXPERIMENTAL
Intervention: Oral vitamin D (50,000 U)
Number of subjects: 328

Group type: COMPARATOR
Intervention: No vitamin D supplementation (control)
Number of subjects: 328
Study: 27477798

Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraoperative conventional X-ray cholangiography (reference group)
Number of subjects: 120
Study: 25420552

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate plus sucrose (0.4 g · kg(‐1) each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric sucrose control (0.8 g · kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with immediate ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with overnight ingestion
Number of subjects: 0
Study: 22905153

Group type: EXPERIMENTAL
Intervention: Experimental group (stress task)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no stress task)
Number of subjects: 81
Study: 21078735

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 18197744

Group type: EXPERIMENTAL
Intervention: Diabetes group visits (GVs)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 15673380

Group type: EXPERIMENTAL
Intervention: Increased daytime SD12 (Poincare dimension)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Increased 24-hour SD12 (Poincare dimension)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Decreased ln ULF (ultra low frequency)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: History of prior MI
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 740
Study: 12917847

Group type: EXPERIMENTAL
Intervention: Combined group (balance and resistance training)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Balance group (balance training only)
Number of subjects: 15
Study: 10624069

Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms/kg bolus followed by infusion of up to 100 micrograms/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study: 8943670

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 139

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Megestrol acetate and Tamoxifen
Number of subjects: 139
Study: 1681268

Group type: EXPERIMENTAL
Intervention: Interferon (52 megaunits for an average of 30 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study: 6378307

Group type: EXPERIMENTAL
Intervention: Fenclofenac
Number of subjects: 63

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 63
Study: 30476584

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Tofacitinib overall cohort (average dose 10 mg twice daily)
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Tofacitinib overall cohort
Number of subjects: 1157
Study: 28032435

Group type: EXPERIMENTAL
Intervention: Short rest (30 s) combined with low load (20 RM) (SL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long rest (3 min) and high load (8 RM) (LH)
Number of subjects: 20
Study: 26598418

Group type: EXPERIMENTAL
Intervention: Midazolam during the procedure
Number of subjects: 150

Group type: COMPARATOR
Intervention: No sedative treatment
Number of subjects: 150
Study: 25176289

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus medical therapy
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 1220
Study: 22484664

Group type: EXPERIMENTAL
Intervention: Nitrite therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose nitrite infusion
Number of subjects: 0
Study: 20204967

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0
Study: 17659837

Group type: EXPERIMENTAL
Intervention: SB‐705498 (400mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17822338

Group type: EXPERIMENTAL
Intervention: Long-acting methylphenidate (Medikinet retard, MPH-MR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 14764790

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study: 10835790

Group type: EXPERIMENTAL
Intervention: Guideline development process
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Identified barriers to clinical change
Number of subjects: 48
Study: 9105648

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 19
Study: 8241229

Group type: EXPERIMENTAL
Intervention: Deflazacort, 1.5 mg/kg/day, tapered to 0.25 mg/kg/day after 2-3 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Prednisone, 1 mg/kg/day, tapered to 0.15 mg/kg/day after 2-3 weeks
Number of subjects: 31
Study: 3516202

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 205
Study: 31259628

Group type: EXPERIMENTAL
Intervention: Reduced in-treatment systolic blood pressure (SBP)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Non-ISH patients
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Reduction in in-treatment SBP
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Interaction of SBP reduction and AF prevention
Number of subjects: 1320
Study: 29059313

Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hypoxia (85% SpO2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hypercapnia
Number of subjects: 23
Study: 26063441

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blocker) administered in a double-blind, placebo-controlled study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 23719216

Group type: EXPERIMENTAL
Intervention: 8-week exercise programme
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 68
Study: 22114276

Group type: EXPERIMENTAL
Intervention: Self-induced motion parallax with binocular viewing conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-induced motion parallax with monocular viewing conditions
Number of subjects: 0
Study: 18594955

Group type: EXPERIMENTAL
Intervention: Viewing children answering yes‐no questions about a transgression (Experiments 1 and 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rating adults who provided truthful or fabricated accounts (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Types of deceivers (children versus adults) and interviews (closed‐ended questions versus extended accounts) (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of deceptive scenario (naturalistic vs. experimentally‐manipulated) (Experiment 4)
Number of subjects: 0
Study: 16523267

Group type: EXPERIMENTAL
Intervention: Liquorice gel (control + 2.5% liquorice extract)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control gel (8% acid‐hydrolyzed corn starch, 25% maltitol syrup, water)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Liquorice gel
Number of subjects: 16
Study: 12602644

Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-occurring substance abuse, treatment nonadherence, and outpatient services intensity
Number of subjects: 0
Study: 11014510

Group type: EXPERIMENTAL
Intervention: Classroom-based DHE lesson plus two small-group sessions
Number of subjects: 449

Group type: COMPARATOR
Intervention: Single classroom-based DHE lesson
Number of subjects: 449
Study: 9360781

Group type: EXPERIMENTAL
Intervention: Cyclosporine stopped on day 60
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cyclosporine continued for 180 days
Number of subjects: 103
Study: 7903326

Group type: EXPERIMENTAL
Intervention: ipsapirone 5 mg t.i.d.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg t.i.d.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: diazepam 5 mg t.i.d.
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study: 3936946

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Mitomycin‐C + FT 207 + OK 432 + PSK)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chemotherapy (Mitomycin‐C + FT 207)
Number of subjects: 58
Study: 31566399

Group type: EXPERIMENTAL
Intervention: Imagery-based intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 150
Study: 30281320

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3001

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3001
Study: 29789969

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Letrozole
Number of subjects: 195

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 195
Study: 26701357

Group type: EXPERIMENTAL
Intervention: BD FlowSmart infusion set
Number of subjects: 85
Study: 25037617

Group type: EXPERIMENTAL
Intervention: Technical Performance Score (TPS) - Class 1 (optimal), Class 2 (adequate), Class 3 (inadequate)
Number of subjects: 549
Study: 22349482

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg ingested on 2 separate days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21028997

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study: 17342402

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Empiric PPI treatment
Number of subjects: 2588

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 2588
Study: 15187379

Group type: EXPERIMENTAL
Intervention: Post-prandial supine posture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-prandial sitting posture
Number of subjects: 0
Study: 11681223

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 100
Study: 9575461

Group type: EXPERIMENTAL
Intervention: Personalized letter from the general practitioner recommending mammography
Number of subjects: 473

Group type: COMPARATOR
Intervention: Control group (no letter)
Number of subjects: 473
Study: 8195335

Group type: EXPERIMENTAL
Intervention: Human biosynthetic growth hormone (HGH; 12 IU/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2958398

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 10 mg sublingually
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually followed by Isosorbide dinitrate (ISDN) 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 20
Study: 29022736

Group type: EXPERIMENTAL
Intervention: Skills & Resiliency Track (n = 97)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined Track (n = 38)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Trauma Track (n = 34)
Number of subjects: 200
Study: 27608604

Group type: EXPERIMENTAL
Intervention: Anodal stimulation of left dlPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation of left dlPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right dlPFC stimulation (both anodal and cathodal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline impulsivity analysis
Number of subjects: 0
Study: 24690370

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36